

# Molecular markers for discriminating *Streptococcus pyogenes* and *S. dysgalactiae* subspecies *equisimilis*

D. J. McMillan · T. Vu · P. V. Bramhachari · S. Y. Kaul ·  
A. Bouvet · M. S. Shaila · M. G. Karmarkar ·  
K. S. Sriprakash

Received: 18 October 2009 / Accepted: 13 February 2010 / Published online: 12 March 2010  
© Springer-Verlag 2010

**Abstract** Given the increasing aetiological importance of *Streptococcus dysgalactiae* subspecies *equisimilis* in diseases which are primarily attributed to *S. pyogenes*, molecular markers are essential to distinguish these species and delineate their epidemiology more precisely. Many clinical microbiology laboratories rely on agglutination reactivity and biochemical tests to distinguish them. These methods have limitations which are particularly exacerbated when isolates with mixed properties are encountered. In order to provide additional distinguishing parameters that could be used to unequivocally discriminate these two common pathogens, we assess here three molecular targets: the *speB*

gene, intergenic region upstream of the *scpG* gene (IRSG) and virPCR. Of these, the former two respectively gave positive and negative results for *S. pyogenes*, and negative and positive results for *S. dysgalactiae* subsp. *equisimilis*. Thus, a concerted use of these nucleic acid-based methods is particularly helpful in epidemiological surveillance to accurately assess the relative contribution of these species to streptococcal infections and diseases.

## Introduction

*Streptococcus pyogenes* and *S. dysgalactiae* subspecies *equisimilis* are closely related Gram-positive bacteria that colonise the skin and respiratory tract of humans. *S. pyogenes* infection is associated with a wide range of diseases, which include relatively benign and common diseases (such as bacterial pharyngitis, impetigo and scarlet fever), potentially fatal invasive diseases (such as necrotising fasciitis and toxic shock syndrome) and rheumatic heart disease [1]. Together, these diseases are estimated to kill half a million people each year [2]. *S. dysgalactiae* subsp. *equisimilis*, which occupies the same tissue sites as *S. pyogenes*, was previously considered to be a less pathogenic organism and causes infections opportunistically [3]. *S. dysgalactiae* subsp. *equisimilis* expresses many of the same virulence factors (including the M-protein, C5a peptidase, streptokinase, fibronectin binding proteins and plasminogen receptors) as those expressed by *S. pyogenes* [4–9] and can cause a similar spectrum of diseases in humans as *S. pyogenes* [3, 10, 11].

In many populations, the *S. dysgalactiae* subsp. *equisimilis* colonisation rate in the throat and the rate of its recovery from pharyngitis exceed that of *S. pyogenes* [12]. The relative contribution by these species to the disease burden could vary considerably between communities and populations

---

D. J. McMillan · T. Vu · S. Y. Kaul · K. S. Sriprakash (✉)  
Bacterial Pathogenesis Laboratory,  
The Queensland Institute of Medical Research (QIMR),  
300, Herston Road,  
Brisbane, QLD 4006, Australia  
e-mail: sriS@qimr.edu.au

D. J. McMillan  
Griffith Medical Research College, Griffith University  
and the Queensland Institute of Medical Research (QIMR),  
Herston, QLD, Australia

S. Y. Kaul · M. G. Karmarkar  
Department of Microbiology, KEM Hospital,  
Mumbai, India

P. V. Bramhachari · M. S. Shaila  
Department of Microbiology and Cell Biology,  
Indian Institute of Science,  
Bangalore, India

A. Bouvet  
Université Paris Descartes,  
Service de Microbiologie-Hygiène, Hôtel Dieu AP-HP,  
Centre National de Référence des Streptocoques LA-SGA-A,  
Paris, France

[13, 14]. There is a paucity of information on streptococcal disease burden in many resource-poor nations [15]. The lack of definitive and rapid tests to differentiate these species and the perception among clinicians that *S. dysgalactiae* subsp. *equisimilis* is generally non-pathogenic may also have contributed to this paucity. Recent studies on invasive disease due to beta-haemolytic streptococci of groups other than A and B concluded distinct clinical manifestations in some populations [16–18]. These studies recommended increased awareness of *S. dysgalactiae* subsp. *equisimilis* as a human pathogen and emphasise the importance of the identification of beta-haemolytic streptococci at the species level.

It is generally difficult to distinguish *S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis* on a morphological basis, as both species are usually large colony forming with similar haemolysis patterns. These and other beta-haemolytic streptococci are traditionally differentiated on the basis of differences in carbohydrate on the bacterial surface and sensitivity to bacitracin [19]. Additional diagnostics such as the PYR reaction (for L-pyrrolidonyl- $\beta$ -naphthylamide aminopeptidase) may be used as confirmatory tests, but are not routine procedures in many clinical microbiology laboratories. Whereas the group A carbohydrate is found in *S. pyogenes*, it has also been found in *S. dysgalactiae* subsp. *equisimilis* in rare cases [5, 20]. Positive reactivity to group C or G antigen is given by *S. dysgalactiae* subsp. *equisimilis*, *S. dysgalactiae* subsp. *dysgalactiae*, *S. equi*, *S. canis* and *S. anginosus* [5, 20, 21]. The bacitracin sensitivity test can sometimes give false-positive results [19]. While the PYR test has excellent specificity and sensitivity in discriminating *S. pyogenes* from *S. dysgalactiae* subsp. *equisimilis*, other bacteria commonly found in the same habitat may also give a positive reaction [22], and the test performed less well in routine diagnostic laboratory settings, sometimes giving weaker reactions [23]. In order to provide additional distinguishing parameters that could be used to discriminate these species, we assess here three molecular targets.


## Materials and methods

*S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis* isolates were collected from two different geographical regions, India and Australia. The three isolates with unusual characteristics were from Europe. The bacteria were grown on Todd–Hewitt agar supplemented with 2% horse blood. Group carbohydrates were determined using the Prolex Streptococcal Grouping Latex Kit (Pro-Lab Diagnostics). The PYR test was performed according to the manufacturer's instructions (Becton Dickinson). DNA was extracted using purification kits (QIAGEN Inc.). The polymerase chain reaction (PCR) conditions were as follows. For *speB*:

denaturation 94°C/30 s, annealing 55°C/30 s, extension 72°C/90 s; forward and reverse primers were GGTTCTGCAGG TAGCTCTCG and TGCCTACAACAGCACTTTGG. For the intergenic region upstream of the *scpG* gene (IRSG): the conditions were the same as above and the primers were CAACACATAACCACCTTCTGGA and TTGCAAGTGCG TCACAAGAT. The primers and conditions for virPCR were as described previously [24, 25]. Sequence typing (*emm* typing) was performed as described by Beall et al. [26] and sequencing the gene for rRNA was carried out after amplifying with universal primers [27].

## Results and discussions

The rationales for the selection of the targets are as follows. Comparative microarray analysis showed that the gene encoding streptococcal cysteine protease, *speB*, found ubiquitously in *S. pyogenes* isolates [28, 29], is absent in *S. dysgalactiae* subsp. *equisimilis* [30]. Furthermore, a *speB* orthologue has not been reported in other bacteria. Hence, the PCR primers targeting this gene are expected to be specific for *S. pyogenes*. Indeed, a PCR for *speB* has been suggested as a diagnostic test for the *S. pyogenes* aetiology of necrotising fasciitis [31]. The remaining two targets are based on the sequence differences in *S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis* upstream of the gene for C5a peptidase (*scpA* and *scpG*, respectively). The physical locations of *scpA*, *emm* (gene for M protein) and the regulator *mga* in the *S. pyogenes* genome are close to each other and are amplifiable by PCR (virPCR; [24, 25]). Depending on the architecture of this chromosomal region, the amplicon arising from virPCR is about 4–7 kb. All *S. dysgalactiae* subsp. *equisimilis* isolates possess *emm* and *scpG* genes [10, 32]. However, previous studies [7, 33] revealed that the *emm* and *scpG* genes in the *S. dysgalactiae* subsp. *equisimilis* genome are not physically linked and the



**Fig. 1** Organisation of the intergenic region upstream of *scpG* (IRSG) of *Streptococcus dysgalactiae* subsp. *equisimilis*. The virPCR primers (dashed arrows) and the IRSG primers (solid arrows) are shown. The length virPCR amplifiable region is somewhat variable, but in more than 98% of *S. dysgalactiae* subsp. *equisimilis* isolates, it is about 2 kb. Within this region, the segment defined by IRSG PCR primers is highly conserved and targets a hypothetical protein

**Table 1** Molecular and biochemical tests carried out on 167 *S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis* isolates from Australia and India

Group carbohydrate	Number of isolates	Number of <i>emm</i> types or subtypes	PYR test	IRSG PCR	<i>speB</i> PCR	virPCR size (kb)			
						~2	3	4	>4–7
A	58	41	+	–	+	0	0	1	57
G	98	31	–	+	–	98	0	0	0
C	11	5	–	+	–	9	1	1	0

sequences immediately upstream of *scpG* exhibit mosaic structure [34]. However, the virPCR designed for *S. pyogenes* also gave a product with *S. dysgalactiae* subsp. *equisimilis*, but the amplicon was only about 2 kb [33–35], suggesting that the primer binding sites may be conserved. We sequenced the virPCR products from diverse *S. dysgalactiae* subsp. *equisimilis* strains and found that an open reading frame for a hypothetical protein within the IRSG is highly conserved in all of the strains (Fig. 1) and is absent in *S. pyogenes*. This allowed us to design *S. dysgalactiae* subsp. *equisimilis*-specific IRSG PCR primers.

*S. pyogenes* ( $n=58$ ) and *S. dysgalactiae* subsp. *equisimilis* ( $n=109$ ) isolates in this study belong to 41 and 36 distinct *emm* (sub)types, respectively, suggesting that they are highly diverse (Table 1). The collection also represents multiple isolates of the same *emm* type. We have shown previously that horizontal gene transfers mediated by phages and conjugative transposons between these species are ongoing events and occur with greater frequencies among isolates from highly endemic regions [35]. Therefore, it is all the more necessary to show species-specific distribution of the target genes among the isolates from highly endemic regions. Clonal diversity and two distinct geographical sources of isolates, one of them (India) being highly endemic for streptococcal infection, fulfil the requirement in this regard.

All of the strains listed in Table 1 were beta-haemolytic on blood agar plates and possessed group A, C or G carbohydrate. The isolates expressing group A carbohydrate were PYR-positive, and the isolates expressing the group C or G antigen were PYR-negative. All of the isolates presumptively identified as *S. pyogenes* based on the above reactions were positive for the *speB* amplicon, whereas none of the *S. dysgalactiae* subsp. *equisimilis* isolates were positive for this reaction. The IRSG assay also proved highly discriminatory, as all *S. dysgalactiae* subsp. *equisimilis* isolates tested produced the expected product of about 500 bp, and none of the *S. pyogenes* isolates gave this amplicon. All PCRs were

performed with appropriate positive controls and template-negative controls. Thus, *speB* and IRSG PCRs together unequivocally distinguish *S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis*.

As reported earlier, the virPCR gave products with both the *S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis* isolates in this study (Table 1). As expected, DNA from all of the *S. pyogenes* isolates gave approximately 4–7-kb product. By contrast, the reaction gave approximately 2-kb products from 107 of the 109 *S. dysgalactiae* subsp. *equisimilis* isolates. One *S. dysgalactiae* subsp. *equisimilis* isolate yielded a 3-kb product and another a 4-kb product. Both of these isolates expressed group C carbohydrate. Sequence analysis of these variant virPCR products (data not shown) revealed insertions within the mosaic regions upstream of the C5a peptidase gene. However, the region of the hypothetical open reading frame targeted by the IRSG primers is conserved (Fig. 1).

Ongoing cross-species horizontal gene transfers [33, 35, 36] could give rise to isolates with mixed characteristics. In this study, three isolates with mixed characteristics were tested. Two isolates (2005-0193 and 2006-0098) that were *S. dysgalactiae* subsp. *equisimilis* as judged by negative reaction to the PYR test but showed agglutination reaction with the group A reagent were also tested by PCRs (Table 2). Both were positive for IRSG PCR and negative for *speB* PCR. The size of the virPCR amplicons were 2 kb. We further confirmed the identity of these isolates as *S. dysgalactiae* subsp. *equisimilis* by 16S rRNA gene sequencing (data not shown). Another isolate (2007-0217) was *S. pyogenes* as shown by PYR positivity, group A carbohydrate reactivity and rRNA gene sequence. However, 2007-0217 belonged to *emm* stg1750, a type normally found in *S. dysgalactiae* subsp. *equisimilis*, suggesting horizontal transfer of the *emm* gene. This isolate was *speB*-positive and IRSG-negative (Table 2). Furthermore, the virPCR product is 7 kb long and revealed physical proximity of the *emm* locus to the *scpA* gene (data not shown).

**Table 2** Molecular and biochemical tests carried out on three unusual *S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis* isolates

Strain name	Group carbohydrate	<i>emm</i> type	PYR test	IRSG PCR	<i>speB</i> PCR	virPCR (kb)
2005-0193	A	stg6	–	+	–	~2
2006-0098	A	stg6	–	+	–	~2
2007-0217	A	stg1750	+	–	+	~7

Recently, a real-time PCR and a low-density microarray were developed to distinguish *S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis*. These assays are based on a common target for both species and another one specific for *S. pyogenes* [37]. The authors recognised that their diagnostic system does not have a positive test for *S. dysgalactiae* subsp. *equisimilis*. By choosing specific targets for each of the species (*speB* and IRSG PCRs for *S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis*, respectively), we have overcome this limitation. It may be noted that none of the molecular markers thus far described differentiate between group G and C carbohydrate expressing *S. dysgalactiae* subsp. *equisimilis*, suggesting that the acquisition of differences in group carbohydrate may have preceded that of molecular markers.

In summary, the three PCRs proposed here offer excellent discriminatory power in identifying common beta-haemolytic streptococcal human pathogens. The tests could be particularly useful in epidemiological surveillance to accurately assess the relative contribution of *S. pyogenes* and *S. dysgalactiae* subsp. *equisimilis* to streptococcal infections and diseases. Current clinical management of infections owing to these species are not different, as both have remained sensitive to penicillin. However, resistance to fluoroquinolone in *S. pyogenes* has been found to be horizontally acquired from *S. dysgalactiae* [38, 39]. Horizontal gene transfers have the ability to rapidly change in population structure, which, in turn, may require tailored management in the future. In the light of these observations, we believe that it would be prudent to identify the definitive aetiology of streptococcal infections and diseases.

**Acknowledgements** This work was funded through an Australian Government National Health and Medical Research Council (NHMRC) Program Grant, the National and International Research Alliances Program of Queensland, Australia.

## References

- Cunningham MW (2000) Pathogenesis of group A streptococcal infections. *Clin Microbiol Rev* 13(3):470–511
- Carapetis JR, Steer AC, Mulholland EK et al (2005) The global burden of group A streptococcal diseases. *Lancet Infect Dis* 5(11):685–694
- Efstratiou A (1997) Pyogenic streptococci of Lancefield groups C and G as pathogens in man. *Soc Appl Bacteriol Symp Ser* 26:72S–79S
- Bisno AL, Craven DE, McCabe WR (1987) M proteins of group G streptococci isolated from bacteremic human infections. *Infect Immun* 55(3):753–757
- Brandt CM, Haase G, Schnitzler N et al (1999) Characterization of blood culture isolates of *Streptococcus dysgalactiae* subsp. *equisimilis* possessing Lancefield's group A antigen. *J Clin Microbiol* 37(12):4194–4197
- Cleary PP, Peterson J, Chen C et al (1991) Virulent human strains of group G streptococci express a C5a peptidase enzyme similar to that produced by group A streptococci. *Infect Immun* 59(7):2305–2310
- Geyer A, Schmidt KH (2000) Genetic organisation of the M protein region in human isolates of group C and G streptococci: two types of multigene regulator-like (*mgrC*) regions. *Mol Gen Genet* 262(6):965–976
- Kalia A, Bessen DE (2003) Presence of streptococcal pyrogenic exotoxin A and C genes in human isolates of group G streptococci. *FEMS Microbiol Lett* 219(2):291–295
- Schnitzler N, Podbielski A, Baumgarten G et al (1995) M or M-like protein gene polymorphisms in human group G streptococci. *J Clin Microbiol* 33(2):356–363
- Ikebe T, Murayama S, Saitoh K et al (2004) Surveillance of severe invasive group-G streptococcal infections and molecular typing of the isolates in Japan. *Epidemiol Infect* 132(1):145–149
- Williams GS (2003) Group C and G streptococci infections: emerging challenges. *Clin Lab Sci* 16(4):209–213
- Bramhachari PV, Kaul SY, McMillan DJ et al (2009) Disease burden due to *Streptococcus dysgalactiae* subsp. *equisimilis* (group G and C streptococci; GGS/GCS) is higher than due to *S. pyogenes* among Mumbai school children. *J Med Microbiol* 59:220–223
- Lindbaek M, Høiby EA, Lermark G et al (2005) Clinical symptoms and signs in sore throat patients with large colony variant beta-haemolytic streptococci groups C or G versus group A. *Br J Gen Pract* 55(517):615–619
- McDonald M, Towers RJ, Andrews RM et al (2007) Epidemiology of *Streptococcus dysgalactiae* subsp. *equisimilis* in tropical communities, Northern Australia. *Emerg Infect Dis* 13(11):1694–1700
- Steer AC, Law I, Matatolu L et al (2009) Global *emm* type distribution of group A streptococci: systematic review and implications for vaccine development. *Lancet Infect Dis* 9(10):611–616
- Brandt CM, Spellerberg B (2009) Human infections due to *Streptococcus dysgalactiae* subspecies *equisimilis*. *Clin Infect Dis* 49(5):766–772
- Broyles RW, Chou AF, Mattachione S et al (2009) The effect of adverse medical events on spending on inpatient care. *Qual Manag Health Care* 18(4):315–325
- Takahashi T, Sunaoshi K, Sunakawa K et al (2009) Clinical aspects of invasive infections with *Streptococcus dysgalactiae* ssp. *equisimilis* in Japan: differences with respect to *Streptococcus pyogenes* and *Streptococcus agalactiae* infections. *Clin Microbiol Infect* (in press)
- Facklam RR, Thacker LG, Fox B et al (1982) Presumptive identification of streptococci with a new test system. *J Clin Microbiol* 15(6):987–990
- Tanaka D, Isobe J, Watahiki M et al (2008) Genetic features of clinical isolates of *Streptococcus dysgalactiae* subsp. *equisimilis* possessing Lancefield's group A antigen. *J Clin Microbiol* 46(4):1526–1529
- Facklam R (2002) What happened to the streptococci: overview of taxonomic and nomenclature changes. *Clin Microbiol Rev* 15(4):613–630
- Chen CH, Huang LU, Lee JH et al (1997) Presumptive identification of streptococci by pyrrolidonyl-beta-naphthylamide (PYR) test. *Zhonghua Yi Xue Za Zhi (Taipei)* 59(4):259–264
- Wu TC, Williams EC, Conville PS (1987) Rapid identification of group A streptococci by the Strep-A-Fluor system. *Diagn Microbiol Infect Dis* 6(1):5–9
- Gardiner D, Hartas J, Currie B et al (1995) Vir typing: a long-PCR typing method for group A streptococci. *PCR Methods Appl* 4(5):288–293
- Hartas J, Hibble M, Sriprakash KS (1998) Simplification of a locus-specific DNA typing method (Vir typing) for *Streptococcus pyogenes*. *J Clin Microbiol* 36(5):1428–1429
- Beall B, Facklam R, Thompson T (1996) Sequencing *emm*-specific PCR products for routine and accurate typing of group A streptococci. *J Clin Microbiol* 34(4):953–958
- Woo PC, Tse H, Chan KM et al (2004) “*Streptococcus milleri*” endocarditis caused by *Streptococcus anginosus*. *Diagn Microbiol Infect Dis* 48(2):81–88
- DelVecchio A, Maley M, Currie BJ et al (2002) NAD-glycohydrolase production and *speA* and *speC* distribution in Group A streptococcus

- (GAS) isolates do not correlate with severe GAS diseases in the Australian population. *J Clin Microbiol* 40(7):2642–2644
29. Tyler SD, Johnson WM, Huang JC et al (1992) Streptococcal erythrogenic toxin genes: detection by polymerase chain reaction and association with disease in strains isolated in Canada from 1940 to 1991. *J Clin Microbiol* 30(12):3127–3131
  30. Davies MR, McMillan DJ, Beiko RG et al (2007) Virulence profiling of *Streptococcus dysgalactiae* subspecies *equisimilis* isolated from infected humans reveals 2 distinct genetic lineages that do not segregate with their phenotypes or propensity to cause diseases. *Clin Infect Dis* 44(11):1442–1454
  31. Louie L, Simor AE, Louie M et al (1998) Diagnosis of group A streptococcal necrotizing fasciitis by using PCR to amplify the streptococcal pyrogenic exotoxin B gene. *J Clin Microbiol* 36(6):1769–1771
  32. Brandt CM, Schweizer KG, Holland R et al (2005) Lack of mitogenic activity of *speG*- and *speG(dys)*-positive *Streptococcus dysgalactiae* subspecies *equisimilis* isolates from patients with invasive infections. *Int J Med Microbiol* 295(8):539–546
  33. Sriprakash KS, Hartas J (1996) Lateral genetic transfers between group A and G streptococci for M-like genes are ongoing. *Microb Pathog* 20(5):275–285
  34. Sriprakash KS, Hartas J (1997) Genetic mosaic upstream of *scpG* in human group G streptococci contains sequences from group A streptococcal virulence regulon. *Adv Exp Med Biol* 418:749–751
  35. Davies MR, Tran TN, McMillan DJ et al (2005) Inter-species genetic movement may blur the epidemiology of streptococcal diseases in endemic regions. *Microbes Infect* 7(9–10):1128–1138
  36. Mylvaganam H, Bruun T, Vindenes HA et al (2009) Molecular epidemiological investigation of an outbreak of invasive beta-haemolytic streptococcal infection in western Norway. *Clin Microbiol Infect* 15(3):245–252
  37. Dawson ED, Taylor AW, Smagala JA et al (2009) Molecular detection of *Streptococcus pyogenes* and *equisimilis* subsp. *equisimilis*. *Mol Biotechnol* 42(1):117–127
  38. Duesberg CB, Malhotra-Kumar S, Goossens H et al (2008) Interspecies recombination occurs frequently in quinolone resistance-determining regions of clinical isolates of *Streptococcus pyogenes*. *Antimicrob Agents Chemother* 52(11):4191–4193
  39. Pletz MW, McGee L, Van Beneden CA et al (2006) Fluoroquinolone resistance in invasive *Streptococcus pyogenes* isolates due to spontaneous mutation and horizontal gene transfer. *Antimicrob Agents Chemother* 50(3):943–948